Stock Price & Analysis

Analysis and Insights

Technical Analysis:

DVA's stock price has shown resilience, with a current price of $149.51 as of 2025-03-24. The stock is trading near its 200-day moving average of $152.86, indicating a neutral trend. The Relative Strength Index (RSI) is at 50.40, suggesting the stock is neither overbought nor oversold.

Valuation Analysis:

DVA has a Forward P/E ratio of 15.76, which is lower than the industry average of 21.96. The PEG ratio of 0.86 indicates the stock is undervalued relative to its growth prospects.

Market Trends and Sentiment:

The healthcare sector has been performing well, with a year-to-date gain of 8%, outperforming the broader market. DVA's short interest increased to 5.97%, reflecting some bearish sentiment. However, the stock has shown strong long-term performance, gaining 57.3% over the past year.

Analyst Sentiment:

Analysts have a cautious outlook on DVA, with a consensus "Hold" rating and a price target of $169. Recent earnings misses and revenue growth concerns have tempered enthusiasm.

Conclusion:

While DVA's defensive nature and lower valuation are positive, the earnings miss and high short interest warrant caution. It may be wise to hold or wait for further positive developments before making a decision.

DVA stock is predicted to reach $170 by the end of 2025, driven by its defensive qualities in a volatile market and analyst price targets. Barclays recently raised its target to $169, reflecting confidence in the stock's stability and potential breakout despite short-term declines.

The S1 support level for DVA Stock is $141.82 ,The R1 resistant level for DVA Stock is $151.93.

As of the end of day on 2025-03-24, the price of DVA Stock was $149.51.

The target price for DVA Stock according to analyst rating is 172.00, with the highest price target at 184.00 and the lowest at 165.00. Analysts have a Hold rating on DVA Stock overall.

The market cap of DVA is $12.0B.

DaVita Inc. (DVA) is not overvalued based on current metrics. Here's the analysis:

1. Valuation Metrics: DVA's PE ratio (14.73) is lower than the industry average, and its EV/EBITDA (13.94) is moderate. The price-to-sales ratio (1.02) and price-to-book ratio (2.65) are reasonable, though the lack of dividend yield (0%) may concern some investors.

2. Financial Performance: Steady revenue growth, fluctuating but positive net income, and high ROE (93.14%) indicate strong financial health and efficient equity use.

3. Short Interest: 5.97% short interest suggests some bearish sentiment, but recent stock performance has been positive.

4. Market Context: Despite broader market overvaluation, DVA's metrics and defensive nature make it a stable choice during economic uncertainty.

In conclusion, DVA appears fairly valued with defensive strengths.

DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and also includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.

DVA stock is predicted to reach around $300 by 2030, driven by sustained growth in the IT services sector and positive analyst sentiment. The stock has shown recent positive movement, with a 1.53% increase in the regular market, and analysts have raised their price targets, indicating confidence in its future performance.

DVA has a total of 70000 employees.